OPTIMIZATION OF INFECTIOUS DISEASES THERAPY ACCORDING TO CHANGES IN THE IMMUNE STATUS PATIENS

  • Ольга Сорокіна Candidate of Medical Sciences, Associate Professor of Department of General and Clinical Immunology and Allergology, V.N. Karazin Kharkov National University
  • Тетяна Лядова Doctor of medical sciences, professor, Head of the Department of General and Clinical Immunology and Allergology, V.N. Karazin Kharkov National University, Kharkiv
  • Микола Попов Doctor of medical sciences, professor of Department of General and Clinical Immunology and Allergology, V.N. Karazin Kharkov National University Kharkiv
  • Діана Дорош Assistant of Department of General and Clinical Immunology and Allergology, V.N. Karazin Kharkov National University Kharkiv, Ukraine
  • Ксенія Векліч Assistant of Department of General and Clinical Immunology and Allergology, V.N. Karazin Kharkov National University. Kharkiv, Ukraine
  • Олеся Гололобова Candidate of Medical Sciences, Associate Professor of Department of General and Clinical Immunology and Allergology, V.N. Karazin Kharkov National University. Kharkiv, Ukraine
  • Анастасія Сорокіна Student of Kharkiv National Medical University, Kharkiv, Ukraine
Keywords: infectious diseases, herpesvirus infection, Epstein-Barr virus, chronic EBV infection, immune state, immunocorrection

Abstract

Introduction. Human viral diseases associated with a protracted course, lifelong persistence, chronicity of the process and adverse consequences of the disease are an urgent problem in clinical immunology. Among the many factors that directly affect the immune system, herpesvirus infections deserve special attention. Nowadays optimization of therapy for patients by differentiated administration of immunocorrective therapy is an urgent problem.
The aim of the work is to study the nature of immune disorders in patients with CEBVI and to develop an optimal therapy, according the identified immune
disorders.
Materials and methods of research. 128 patients with CEBVI was examined. Immunophenotyping of lymphocyte subpopulations was carried out using flow laser cytometry on a FACS-Calibur apparatus (USA) using monoclonal antibodies.
Results. According to the results of the study, it was established that monotherapy was highly effective in patients of the 1st group with minor immune disorders before starting treatment. In patients of the 2nd group, with more pronounced disorders, in comparison with the first group, the combination therapy of Valtrex and Neovir was effective in the immunogram. In patients of group 3 with significant disorders of the immune status, the immunogram indices returned to normal only after the use of Valtrex in combination with Alfarekin.
Conclusion. A detailed analysis of the immune parameters of patients with CEBVI revealed discrepancies among patients of the 1st, 2nd and 3rd groups regarding both the degree and nature of immune changes. This is must be taken into account for the successful result of differential immunocorrection in such patients.

Downloads

Download data is not yet available.

References

Барычева Л. Ю., Голубева М. В., Волкова А. В. Факторы и механизмы иммунносупрессии при Эпштейна-Барр вирусной инфекции. Детские инфекции. 2014. №2. С. 28–33.

Дуда О.К. / Клінічні форми хронічної Епштейна-Барр вірусної інфекції: питання сучасної діагностики та лікування / O.K. Дуда, Р.O. Колесников, M.В. Окружнов, В.O.Бойко // Актуальная инфектология. – 2015. – №1 (6). – С. 16-21.

Глей А. І. Хронічні форми Епштейна-Барр вірусної інфекції. Клінічна імунологія. Алергологія. Інфектологія. 2009. № 2. С. 69–71.

Клінічні форми хронічної Епштейна-Барр вірусної інфекції: питання сучасної діагностики та лікування / А. К. Дуда Р. О. Колесник, Н. В. Окружнов, В. А. Бойко. Актуальная инфектология. 2015. № 1 (6). С. 15–20.

Иммунологические критерии назначения иммунокоррегирующих препаратов при инфекционном мононуклеозе у детей / Г. Ф. Железникова, В.В.Иванова, А. С. Левина и др. // Пллергология и иммунология. – 2006. – № 3. – С. 335-336.

Sorokina O. G., Zinchenko Y. Y. Therapeutic use of immunomodulatory drugs in the treatment of patients with Epstain-Barr virus infection. IX International scientific interdisciplinary congress, May 20, Kharkiv National Medical University. Kharkiv, 2016. P. 366–367.

Sorokina O. G. Types of immune reaction at patients with chronic Epstain-Barr infection. Медицина XXI століття : матеріали науково-практичної конференції молодих вчених з міжнародною участю, 23 листопада 2017 р. Харків, 2017. C. 126–127.

Published
2020-12-24
How to Cite
Сорокіна, О., Лядова, Т., Попов, М., Дорош, Д., Векліч, К., Гололобова, О., & Сорокіна, А. (2020). OPTIMIZATION OF INFECTIOUS DISEASES THERAPY ACCORDING TO CHANGES IN THE IMMUNE STATUS PATIENS. Immunology and Allergology: Science and Practice, (3-4), 65-70. https://doi.org/10.37321/immunology.2020.3-4-07